-
With curATime we strive to be at the forefront of innovation by collaborating with the brightest minds of academia and industry. We want to push the boundaries of knowledge and create transformative impact.
Prof. Dr. Johnny Kim
curATime cluster spokesman -
curATime stands for innovation by teamwork and interdisciplinarity. Together, we develop disruptive approaches for the prevention and treatment of cardiovascular diseases.
Priv.-Doz. Dr. Boris Strilic
Deputy cluster spokesman -
curATime is a new challenge for us, not only because of the diversity of cluster participants, but especially because it sets the course into completely new research areas for TRON.
Dr. Tina Büchling
Administrative coordinator curATime -
We want to better understand the pathomechanistic processes of atherothrombosis and identify molecular targets that we can address immunotherapeutically.
Univ.-Prof. Dr. med. Ugur Sahin
curATime Scientist -
curATime is a tremendous opportunity for translating basic discoveries into new therapeutic strategies and the prevention of atherothrombotic diseases.
Univ.-Prof. Dr. med. Wolfram Ruf
curATime Scientist -
The use of AI and Deep Learning for cardiovascular diseases will contribute essentially to the faster and lower-cost development of new drugs, as well as to the improvement of diagnoses and therapies.
Univ.-Prof. Dr. Andreas Dengel
curATime Scientist -
With curATime, we aim to take drug development, diagnostics and prognosis of atherothrombosis to a new level. It is based on highly granular human cohorts with large-scale multi-omics analyses. This will enable us to identify targets and specific signatures directly in humans.
Univ.-Prof. Dr. med. Philipp Wild
curATime Scientist
About us
Our network
curATime is one of 14 future clusters of the "Clusters4Future" initiative of the Federal Ministry of Education and Research. This initiative promotes geographically concentrated partnership structures that work towards a common goal through cooperation between all relevant stakeholders. In this way, different technologies and competencies of a region are re-bundled to provide financial support for Germany's top research at an early stage, thus giving the clusters the opportunities to transform their ideas into future-oriented key technologies and applications.
A core team of experts in the fields of biomarker and thrombosis research, clinical cardiology, immunotherapy, epidemiology and machine learning has come together to establish the cluster. With their complementary expertise and access to extensive population studies (Gutenberg Health Study) and disease cohorts, the curATime core partners, consisting of TRON gGmbH, the University Medical Center of the Johannes Gutenberg University Mainz and the German Research Center for Artificial Intelligence (DFKI) in Kaiserslautern, have excellent prerequisites for achieving the ambitious cluster goals and thus the therapy for combating atherothrombosis that is targeted at the individual patient.
